-
Posted by
Two Blokes Jul 19 -
Filed in
Stock
-
2 views
Euroapi is reorganizing under the FOCUS-27 plan, with significant restructuring costs but expected efficiency gains and free cash flow growth from 2026 onward. Recent European Commission funding and a growing API market position Euroapi for future growth, despite current revenue declines tied to Sanofi. The company is undervalued based on my DCF models, presenting a buying opportunity as more investors recognize its potential and public financing support.
